Allergan receives FDA response letter for prior approval supplement for Restasis container

Allergan has received a complete response letter from the FDA for its prior approval supplement for the multi-dose, preservative free bottle for Restasis, according to a company press release. The FDA requested additional Chemistry, Manufacturing and Controls information for the Restasis (cyclosporine ophthalmic emulsion) 0.05%, multi-dose preservative-free (MDPF) bottle, according to the release.